Stock listing
OTC:ARDS Aridis Pharmaceuticals Inc. Stock
Follow Aridis Pharmaceuticals Inc. into a list and get an email when it puts out news.
Share price · OTC:ARDS
$0.0001 USD 0.0000 (0.0%)
Close on Nov 20, 2026
- Day range
- $0.0001 – $0.0001 USDNov 20, 2026
- Volume
- 1,600 sharesNov 20, 2026
- Market cap
- $4,457 USDAt the close on Nov 20, 2026 · price × 44.57M shares outstanding
- 52-week range
- $0.0001 – $0.0500 USDLowest and highest trades, Nov 24, 2025 – Nov 20, 2026
- Traded on an average day
- $2 USDMedian day 565 shares · 25 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:ARDS · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 1,600 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 900 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 12,000 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 1,520 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 869,540 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 6,100 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | -0.0001 | -50.0% | $0.0002 | $0.0002 | $0.0001 | 374,480 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 1,000 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 15,100 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 195 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | +0.0001 | +100.0% | $0.0002 | $0.0002 | $0.0002 | 1,950 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 3,250 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 10,000 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 600 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 233 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 2,000 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 10,561 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 15,000 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 360 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 1,063 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 1,067 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 10,000 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 10,301 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 4,306 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 7,079 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 11,010 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 1,529 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 139 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 5,724 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 1,029 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 1,044 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 2,752 | |
| $0.0001 | 0.0000 | 0.0% | $0.0014 | $0.0014 | $0.0001 | 10 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 1,087 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 529 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 42,719 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 500 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 2,650 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 1,002 |
- Ticker
- OTC:ARDS
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
Latest news
Aridis Pharmaceuticals Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 5 in all · newest Jun 24, 2024 · oldest 2023
- Decks
- 10 decks · latest February 2024
Valuation
price Nov 20, 2026
- Enterprise value
- No statements on 6ix yet
- P/E
- No statements on 6ix yet
- EV/sales
- No statements on 6ix yet
- EV/EBITDA
- No statements on 6ix yet
- Price/book
- No statements on 6ix yet
- Gross margin
- No statements on 6ix yet
- Operating margin
- No statements on 6ix yet
- Net margin
- No statements on 6ix yet
- Debt to equity
- No statements on 6ix yet
- Beta vs S&P 500
- -0.21
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Aridis Pharmaceuticals Inc. · OTC:ARDS | US$4,457 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -0.21 |
| Chimeric Therapeutics Limited · ASX:CHM | US$292,816 | −US$220,193 | n/a | −0.1× | n/a | 0.2× | −262.8% | 2.5× | n/a |
| CERo Therapeutics Holdings, Inc. · OTC:CERO | US$265,035 | −US$190,890 | n/a | n/a | n/a | n/a | n/a | n/a | 1.47 |
| CDT Equity Inc. · NASDAQ:CDT | US$234,109 | −US$1.49M | n/a | n/a | n/a | 0.0× | n/a | 0.0× | 1.14 |
| GlucoTrack, Inc. · NASDAQ:GCTK | US$217,049 | −US$887,951 | n/a | n/a | n/a | n/a | n/a | n/a | 1.73 |
| Regen BioPharma, Inc. · OTC:RGBP | US$167,528 | US$167,289 | n/a | 0.7× | n/a | n/a | −501.4% | n/a | 1.20 |
| CNBX Pharmaceuticals Inc. · OTC:CNBX | US$160,577 | US$151,090 | n/a | n/a | n/a | n/a | n/a | n/a | 1.78 |
| Fifty 1 Labs Inc. · OTC:FITY | US$118,532 | US$282,021 | n/a | 6,000× | n/a | n/a | n/a | n/a | -1.17 |
| GB Sciences, Inc. · OTC:GBLX | US$81,414 | US$2.07M | n/a | n/a | n/a | n/a | n/a | n/a | -0.46 |
| Lyra Therapeutics, Inc. · OTC:LYRA | US$53,246 | US$14.42M | n/a | 36.2× | n/a | n/a | n/a | n/a | 0.67 |
| ZyVersa Therapeutics, Inc. · OTC:ZVSA | US$810 | US$1.20B | n/a | n/a | n/a | n/a | n/a | n/a | -0.56 |
| Median of the others | US$164,053 | US$159,190 | 18.5× | 0.1× | −382.1% | 1.3× | 1.14 |
Team and board
Officers
| Officer | Role |
|---|---|
| Vu L. Truong | Founder, Chief Executive Officer and Director |
| Jeffrey J. Fessler | Acting General Counsel |
| Elizabeth Leininger | Vice President of Regulatory Affairs and Quality |
| Franco Merckling | Senior Vice President, Operations |
| Bruno Francois | Head of Limoges Clinical Investigation Center |
| Hasan Jafri | Chief Medical Officer |
| Marin Kollef | Director of Medical ICU and Respiratory Care Services |
Board
| Director | Role |
|---|---|
| Vu L. Truong | Founder, Chief Executive Officer and Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Dec 31, 2025 | Feb 25, 2026 | 0.0% |
| Quarter to Sep 30, 2025 | Nov 28, 2025 | 0.0% |
| Quarter to Jun 30, 2025 | Aug 29, 2025 | 0.0% |
| Quarter to Mar 31, 2025 | May 30, 2025 | −66.7% |
| Quarter to Dec 31, 2024 | Feb 26, 2025 | 0.0% |
| Quarter to Sep 30, 2024 | Nov 29, 2024 | 0.0% |
| Quarter to Jun 30, 2024 | Aug 13, 2024 | 0.0% |
| Quarter to Mar 31, 2024 | May 14, 2024 | |
| Quarter to Dec 31, 2023 | Jan 12, 2024 · After close | |
| Q3 2023 | Nov 3, 2023 · After close |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2023 | Sep 14, 2023 · Before open | |
| Q1 2023 | May 22, 2023 · After close | |
| Q4 2022 | Mar 31, 2023 · After close | |
| Q3 2022 | Nov 21, 2022 · After close | |
| Q2 2022 | Aug 16, 2022 · Before open | |
| Q1 2022 | Apr 1, 2022 · Before open | |
| Q4 2021 | Mar 31, 2022 · After close | |
| Q3 2021 | Nov 10, 2021 · Before open | |
| Q2 2021 | Aug 12, 2021 · After close | |
| Q1 2021 | May 11, 2021 · After close |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (February 2024) | Investor deck | 26 slides | February 2024 |
| Investor Presentation (July 2023) | Investor deck | 27 slides | July 2023 |
| Investor Presentation (April 2023) | Investor deck | 26 slides | April 2023 |
| Investor Presentation (February 2023) | Investor deck | 34 slides | February 2023 |
| Investor Presentation (November 2022) | Investor deck | 30 slides | November 2022 |
| Investor Presentation (January 2022) | Investor deck | 30 slides | Jan 5, 2022 |
| Investor Day (December 2020) | Investor day | 27 slides | Dec 4, 2020 |
| Investor Presentation (June 2020) | Investor deck | 8 slides | Jun 26, 2020 |
| Maxim ID Conference 2020 | Conference | 9 slides | May 5, 2020 |
| PEP Talk Conference 2020 | Conference | 39 slides | Jan 24, 2020 |
Financials
Annual, in USD
Income statement
| Line | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 19.3M | 1.53M | 1.00M | 1.02M | 2.76M | 860.0K | 2.27M | 2.86M |
| Cost of revenue | 23.0M | 0 | 1.93M | 2.15M | ||||
| Gross profit | 1.53M | 1.00M | 1.02M | 2.76M | 860.0K | 342.0K | 714.0K | |
| Research and development | 25.9M | 37.9M | 17.0M | 24.1M | 23.0M | 17.4M | 6.26M | |
| Selling, general and administrative | 7.16M | 7.31M | 6.45M | 6.03M | 3.87M | 3.16M | 1.97M | 3.28M |
| Operating income | -30.0M | -43.7M | -22.4M | -29.1M | -24.1M | -19.7M | -7.88M | -7.91M |
| Depreciation and amortization | 487.0K | 435.0K | 337.0K | 338.0K | 283.0K | 62.0K | 23.0K | 27.0K |
| EBITDA | -29.5M | -43.3M | -22.1M | -28.7M | -23.8M | -19.7M | -7.86M | -7.88M |
| Interest expense | 378.0K | 245.0K | 0 | 0 | 420.0K | 0 | 366.0K | 0 |
| Income before tax | -30.4M | -43.2M | -22.3M | -29.7M | -22.1M | -24.7M | -8.42M | -8.20M |
| Income tax | 378.0K | -912.0K | -405.0K | -695.0K | 2.43M | 4.92M | 538.0K | 0 |
| Net income | -30.7M | -42.3M | -22.3M | -29.0M | -22.1M | -24.7M | -8.42M | -8.20M |
| Earnings per share, basic | -1.64 | -3.44 | -2.44 | -3.43 | -7.02 | -3.12 | -1.07 |
Balance sheet
| Line | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 4.88M | 20.0M | 8.23M | 20.9M | 24.2M | 25.1M | 22.3M | 2.89M |
| Receivables | 1.24M | 237.0K | 368.0K | 413.0K | 2.10M | 67.0K | 522.0K | |
| Inventory | -237.0K | -368.0K | -413.0K | -4.11M | ||||
| Current assets | 11.6M | 26.8M | 15.1M | 28.0M | 24.2M | 25.3M | 22.4M | 3.57M |
| Property, plant and equipment | 1.36M | 1.26M | 1.01M | 1.27M | 750.0K | 39.0K | 42.0K | |
| Total assets | 14.7M | 26.8M | 15.1M | 28.0M | 31.6M | 26.5M | 22.5M | 3.88M |
| Accounts payable | 2.31M | 5.24M | 1.89M | 1.75M | 2.33M | 933.0K | 678.0K | 402.0K |
| Current liabilities | 36.9M | 33.3M | 22.4M | 19.3M | 5.30M | 3.17M | 2.40M | 5.91M |
| Long-term debt | 5.28M | 276.0K | ||||||
| Total debt | 6.13M | 5.98M | 715.0K | |||||
| Total liabilities | 38.9M | 40.9M | 23.8M | 24.3M | 5.30M | 15.0M | 8.76M | 5.91M |
| Shareholders' equity | -24.2M | -13.1M | -8.68M | 3.64M | 26.3M | 11.4M | 13.8M | -2.02M |
| Shares outstanding | 18.8M | 12.3M | 9.17M | 8.46M | 3.15M | 7.89M | 7.89M |
Cash flow
| Line | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -29.1M | -22.9M | -20.5M | -8.16M | -24.3M | -17.6M | -6.09M | -4.49M |
| Capital spending | -82.0K | -530.0K | -367.0K | -174.0K | -677.0K | -698.0K | -15.0K | -1.00K |
| Free cash flow | -29.2M | -23.5M | -20.8M | -8.33M | -24.9M | -18.3M | -6.11M | -4.49M |
| Cash from investing | -82.0K | -530.0K | -367.0K | -174.0K | -1.68M | -698.0K | -15.0K | -1.00K |
| Cash from financing | 14.8M | 34.7M | 8.68M | 4.99M | 25.1M | 21.1M | 25.5M | 3.76M |
| Dividends paid | -4.13M | -1.36M | ||||||
| Share buybacks | 7.96M | 4.99M | 25.1M | 21.1M | 25.8M | 89.0K | ||
| Change in cash | -14.4M | 11.3M | -12.2M | -3.34M | -859.0K | 2.81M | 19.4M | -738.0K |
Cap table
Built by 6ix from Aridis Pharmaceuticals Inc.’s releases
- Common shares
- 44,574,021
- Fully diluted
- 44,574,021
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 44,574,021 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 44,574,021 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Isaac Blech Other companies: X4 Pharmaceuticals, Inc. (Director · Mar 13, 2019 – Mar 13, 2019 · Past); InspireMD Inc. (Director · Jan 22, 2016 – Dec 7, 2016 · Past); Avalo Therapeutics, Inc. (Director · Oct 14, 2015 – Dec 31, 2018 · Past); PDS Biotechnology Corporation (Director · Sep 30, 2015 – Mar 15, 2019 · Past); SpendSmart Networks Inc (Director · Aug 1, 2014 – Jul 19, 2016 · Past); CervoMed Inc. (Director · Jul 24, 2014 – Aug 31, 2016 · Past); Aevi Genomic Medicine LLC (Director · Nov 11, 2013 – Apr 15, 2016 · Past) | Director · Aug 13, 2018 – Aug 13, 2018 · Past |
| Michael Adrian Nazak Other companies: AN2 Therapeutics, Inc. (Chief Accounting Officer · Mar 24, 2022 – Feb 15, 2023 · Past) | Chief Financial Officer · Feb 18, 2021 – Feb 18, 2021 · Past |
| Bruno Francois | Head of Limoges Clinical Investigation Center · Since at least Nov 4, 2026 |
| Elizabeth Leininger | Vice President of Regulatory Affairs and Quality · Since at least Nov 5, 2026 |
| Franco Merckling | Senior Vice President, Operations · Since at least Nov 5, 2026 |
| Fred Kurland | CFO · Aug 13, 2018 – May 4, 2023 · Past |
| Hasan Jafri | Chief Medical Officer · Since at least Jun 15, 2020 |
| Jeffrey J. Fessler | Acting General Counsel · Since at least Nov 5, 2026 |
| Marin Kollef | Director of Medical ICU and Respiratory Care Services · Since at least Nov 4, 2026 |
| Robert K Coughlin | Director · Aug 13, 2018 – Aug 13, 2018 · Past |
All 11 people
| Person | Seat |
|---|---|
| Vu L. Truong | Founder, Chief Executive Officer and Director · Since at least May 12, 2021 |
Log in to ask 6ix AI your own questions about Aridis Pharmaceuticals Inc.